CardinalStone Partners Limited is proud to announce the successful completion of the N21bn Rights Issue of Fidson Healthcare Plc, Nigeria’s foremost indigenous pharmaceutical manufacturer.
The transaction closed at an impressive 117 per cent subscription rate, making it one of the most strongly supported equity capital markets transactions on the Nigerian Exchange Group in recent years.
Acting as Financial Adviser and Issuing House, CardinalStone led the transaction from structuring and regulatory engagement through investor marketing, execution, and final allotment. The successful completion of the Rights Issue reflects the firm’s strong execution capabilities, deep understanding of the Nigerian capital markets, and continued ability to connect credible businesses with long-term domestic capital.
Despite prevailing macroeconomic and liquidity challenges, the 117 per cent oversubscription highlights strong investor confidence in Fidson’s growth strategy and the long-term potential of Nigeria’s healthcare and manufacturing sectors. The strong participation also signals sustained appetite for credible issuers and well-structured investment opportunities within the Nigerian capital markets.
Beyond the immediate success of the capital raise, the transaction represents a significant milestone for Nigeria’s pharmaceutical industry and the broader national economy. At a time when countries around the world are prioritising healthcare security and local manufacturing resilience, the successful funding of an indigenous pharmaceutical leader carries major strategic importance for Nigeria’s future.
Nigeria continues to rely heavily on imported pharmaceutical products and active ingredients, creating significant pressure on foreign exchange demand while exposing the healthcare system to global supply chain disruptions and international market volatility. Expanding local pharmaceutical manufacturing capacity is therefore not only a healthcare priority but also an economic necessity.
The proceeds from the Rights Issue will support Fidson’s expansion across manufacturing infrastructure, product development, and distribution capacity. This investment is expected to deepen local production capabilities, improve access to affordable and quality medicines, strengthen the domestic healthcare value chain, and create more skilled employment opportunities across the sector.
Importantly, the transaction also contributes to Nigeria’s broader industrialisation agenda by supporting local production, reducing import dependence, conserving foreign exchange, and encouraging the development of globally competitive Nigerian manufacturing businesses. The multiplier effect extends beyond healthcare into logistics, packaging, research, distribution, retail, and employment generation across the wider economy.
As Africa’s largest economy continues to pursue economic diversification and sustainable growth, transactions such as this demonstrate the critical role of the capital markets in mobilising private sector funding toward sectors that directly impact national development and citizen wellbeing.
For CardinalStone, the successful execution of the Fidson Rights Issue further reinforces the firm’s position as one of West Africa’s leading independent investment banking franchises. The transaction adds to the firm’s growing track record of landmark capital market mandates across critical sectors of the economy, reflecting its commitment to delivering innovative financial solutions that drive long-term growth and economic transformation.
This transaction represents far more than a successful capital raise; it underscores the growing role of Nigeria’s capital markets in advancing strategic sectors critical to national development. By supporting the expansion of indigenous pharmaceutical manufacturing, the Fidson Rights Issue contributes meaningfully to strengthening healthcare resilience, deepening local industrial capacity, conserving foreign exchange, creating sustainable employment, and positioning Nigeria for a more self-reliant and globally competitive future.
CardinalStone is Nigeria’s leading independent investment banking group, providing integrated solutions across advisory, capital markets, asset management, securities trading, trust services, financing, registrar services, and pensions.
With over N5tn in advised capital markets and M&A transactions, CardinalStone has established itself as one of Africa’s premier financial institutions. The firm was the first securities house to surpass N2tn in transaction value on the Nigerian Exchange and has ranked as the Exchange’s number-one securities firm by value for four consecutive years (2022–2025).
Its market leadership has been recognised through numerous industry awards, including Euromoney’s Africa’s Best Broker Award (2025) and multiple DealMakers Africa Awards (2026) for excellence in equity advisory and capital markets execution.
CardinalStone Partners Limited is proud to announce the successful completion of the N21bn Rights Issue of Fidson Healthcare Plc, Nigeria’s foremost indigenous pharmaceutical manufacturer.
The transaction closed at an impressive 117 per cent subscription rate, making it one of the most strongly supported equity capital markets transactions on the Nigerian Exchange Group in recent years.
Acting as Financial Adviser and Issuing House, CardinalStone led the transaction from structuring and regulatory engagement through investor marketing, execution, and final allotment. The successful completion of the Rights Issue reflects the firm’s strong execution capabilities, deep understanding of the Nigerian capital markets, and continued ability to connect credible businesses with long-term domestic capital.
Despite prevailing macroeconomic and liquidity challenges, the 117 per cent oversubscription highlights strong investor confidence in Fidson’s growth strategy and the long-term potential of Nigeria’s healthcare and manufacturing sectors. The strong participation also signals sustained appetite for credible issuers and well-structured investment opportunities within the Nigerian capital markets.
Beyond the immediate success of the capital raise, the transaction represents a significant milestone for Nigeria’s pharmaceutical industry and the broader national economy. At a time when countries around the world are prioritising healthcare security and local manufacturing resilience, the successful funding of an indigenous pharmaceutical leader carries major strategic importance for Nigeria’s future.
Nigeria continues to rely heavily on imported pharmaceutical products and active ingredients, creating significant pressure on foreign exchange demand while exposing the healthcare system to global supply chain disruptions and international market volatility. Expanding local pharmaceutical manufacturing capacity is therefore not only a healthcare priority but also an economic necessity.
The proceeds from the Rights Issue will support Fidson’s expansion across manufacturing infrastructure, product development, and distribution capacity. This investment is expected to deepen local production capabilities, improve access to affordable and quality medicines, strengthen the domestic healthcare value chain, and create more skilled employment opportunities across the sector.
Importantly, the transaction also contributes to Nigeria’s broader industrialisation agenda by supporting local production, reducing import dependence, conserving foreign exchange, and encouraging the development of globally competitive Nigerian manufacturing businesses. The multiplier effect extends beyond healthcare into logistics, packaging, research, distribution, retail, and employment generation across the wider economy.
As Africa’s largest economy continues to pursue economic diversification and sustainable growth, transactions such as this demonstrate the critical role of the capital markets in mobilising private sector funding toward sectors that directly impact national development and citizen wellbeing.
For CardinalStone, the successful execution of the Fidson Rights Issue further reinforces the firm’s position as one of West Africa’s leading independent investment banking franchises. The transaction adds to the firm’s growing track record of landmark capital market mandates across critical sectors of the economy, reflecting its commitment to delivering innovative financial solutions that drive long-term growth and economic transformation.
This transaction represents far more than a successful capital raise; it underscores the growing role of Nigeria’s capital markets in advancing strategic sectors critical to national development. By supporting the expansion of indigenous pharmaceutical manufacturing, the Fidson Rights Issue contributes meaningfully to strengthening healthcare resilience, deepening local industrial capacity, conserving foreign exchange, creating sustainable employment, and positioning Nigeria for a more self-reliant and globally competitive future.
CardinalStone is Nigeria’s leading independent investment banking group, providing integrated solutions across advisory, capital markets, asset management, securities trading, trust services, financing, registrar services, and pensions.
With over N5tn in advised capital markets and M&A transactions, CardinalStone has established itself as one of Africa’s premier financial institutions. The firm was the first securities house to surpass N2tn in transaction value on the Nigerian Exchange and has ranked as the Exchange’s number-one securities firm by value for four consecutive years (2022–2025).
Its market leadership has been recognised through numerous industry awards, including Euromoney’s Africa’s Best Broker Award (2025) and multiple DealMakers Africa Awards (2026) for excellence in equity advisory and capital markets execution.
